e-learning
resources
London 2016
Tuesday, 06.09.2016
Post-transplant complications: from animal models to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Risk of post-transplantation diabetes mellitus (PTDM) with different calcineurin inhibitors
Benjamin-Alexander Bollmann (Hannover, Germany), Benjamin-Alexander Bollmann, Benjamin Seeliger, Jens Gottlieb, Mark Greer
Source:
International Congress 2016 – Post-transplant complications: from animal models to the bedside
Session:
Post-transplant complications: from animal models to the bedside
Session type:
Poster Discussion
Number:
4646
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Benjamin-Alexander Bollmann (Hannover, Germany), Benjamin-Alexander Bollmann, Benjamin Seeliger, Jens Gottlieb, Mark Greer. Risk of post-transplantation diabetes mellitus (PTDM) with different calcineurin inhibitors. Eur Respir J 2016; 48: Suppl. 60, 4646
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Impact of diabetes mellitus on survival and hospitalization after lung transplantation
Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside
Year: 2016
Study of PFT‘s in patients with type 2 diabetes mellitus and diabetic neuropathy and microangiopathy
Source: Annual Congress 2007 - Lung function and therapy in obstructive lung diseases
Year: 2007
Impact of diabetes mellitus on MDR-TB outcome
Source: International Congress 2018 – Tuberculosis comorbidities
Year: 2018
Hyperglycemia and diabetes mellitus as mortality risk factors in 600 COVID-19 Romanian patients
Source: Virtual Congress 2021 – COVID - 19 around the globe
Year: 2021
Metformin predispose acute exacerbations of COPD patients with insulin-dependent diabetes mellitus>
Source: International Congress 2018 – COPD and extrapulmonary comorbidities
Year: 2018
Tuberculosis and diabetes mellitus: Treatment outcomes using directly observed therapy (DOT)
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015
Risk of development of diabetes mellitus in patients with bronchial asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 323s
Year: 2006
Approach to the diagnostics of early carbon metabolism disorders and diabetes mellitus 2 type in COPD patients
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Pulmonary microangiopathy as a possible complication in patients with diabetes mellitus
Source: Eur Respir J 2004; 24: Suppl. 48, 222s
Year: 2004
Prevalence and impact of Diabetes mellitus (DM) among hospitalized community-acquired pneumonia (CAP) patients
Source: International Congress 2015 – Risk factors and co-morbidities in asthma and COPD
Year: 2015
Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD
Source: Eur Respir J 2008; 32: 962-969
Year: 2008
Role of BMI in the clinical course of COPD patients with type 2 diabetes mellitus
Source: International Congress 2018 – COPD and extrapulmonary comorbidities
Year: 2018
COVID-19: Impact in adult patients with premorbid disease: Metabolic diseases (diabetes, obesity)
Source: ERS Course 2021 - COVID-19: State of the art
Year: 2021
A study of immunogenetic markers associated With tuberculosis and diabetes mellitus
Source: Annual Congress 2013 –Diagnostic features of tuberculosis II
Year: 2013
Impact of diabetes mellitus (dm) or hypertension and ischaemic heart disease (hd) on cisplatin nephrtotoxicity
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
Comparison of COPD patients with and without diabetes mellitus
Source: Virtual Congress 2020 – Diagnosis and management of COPD
Year: 2020
Risk factors for chronic lung allograft dysfunction (CLAD) in the SysCLAD cohort
Source: International Congress 2015 – Pathogenic mechanisms of lung transplant complications: a focus on CLAD
Year: 2015
A study of the comorbidity of COPD and type 2 diabetes mellitus
Source: International Congress 2018 – COPD and extrapulmonary comorbidities
Year: 2018
Smoking cessation in patients with Diabetes Mellitus (DM)
Source: Virtual Congress 2020 – The role of health care systems in treating tobacco dependence
Year: 2020
Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients
Source: Eur Respir J 2011; 37: 888-894
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept